Exhaled Molecular Fingerprinting in Diagnosis and Monitoring: Validating Volatile Promises.

Medical diagnosis and phenotyping increasingly incorporate information from complex biological samples. This has promoted the development and clinical application of non-invasive metabolomics in exhaled air (breathomics). In respiratory medicine, expired volatile organic compounds (VOCs) are associated with inflammatory, oxidative, microbial, and neoplastic processes. After recent proof of concept studies demonstrating moderate to good diagnostic accuracies, the latest efforts in breathomics are focused on optimization of sensor technologies and analytical algorithms, as well as on independent validation of clinical classification and prediction. Current research strategies are revealing the underlying pathophysiological pathways as well as clinically-acceptable levels of diagnostic accuracy. Implementing recent guidelines on validating molecular signatures in medicine will enhance the clinical potential of breathomics and the development of point-of-care technologies.

[1]  R. Dweik,et al.  Review article: breath analysis in inflammatory bowel diseases , 2015, Alimentary pharmacology & therapeutics.

[2]  D. Wishart,et al.  Translational biomarker discovery in clinical metabolomics: an introductory tutorial , 2012, Metabolomics.

[3]  Ashley Woodcock,et al.  Non-invasive phenotyping using exhaled volatile organic compounds in asthma , 2011, Thorax.

[4]  Bogusław Buszewski,et al.  Human exhaled air analytics: biomarkers of diseases. , 2007, Biomedical chromatography : BMC.

[5]  Frederick B. Marcus,et al.  A systems medicine clinical platform for understanding and managing non- communicable diseases. , 2014, Current pharmaceutical design.

[6]  A Smolinska,et al.  Current breathomics—a review on data pre-processing techniques and machine learning in metabolomics breath analysis , 2014, Journal of breath research.

[7]  F H Krouwels,et al.  Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD , 2011, European Respiratory Journal.

[8]  J. Greve,et al.  Non-alcoholic steatohepatitis: a non-invasive diagnosis by analysis of exhaled breath. , 2013, Journal of hepatology.

[9]  Agnieszka Smolinska,et al.  Profile of volatile organic compounds in exhaled breath changes as a result of gluten-free diet , 2013, Journal of breath research.

[10]  T. J. Vink,et al.  Effect of transportation and storage using sorbent tubes of exhaled breath samples on diagnostic accuracy of electronic nose analysis , 2012, Journal of breath research.

[11]  Gary S Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration , 2015, Annals of Internal Medicine.

[12]  H. Schulz,et al.  Online breath gas analysis in unrestrained mice by hs-PTR-MS , 2014, Mammalian Genome.

[13]  Peter J Sterk,et al.  An electronic nose in the discrimination of patients with asthma and controls. , 2007, The Journal of allergy and clinical immunology.

[14]  J W Dallinga,et al.  A profile of volatile organic compounds in breath discriminates COPD patients from controls. , 2009, Respiratory medicine.

[15]  J André Knottnerus,et al.  Evaluation of diagnostic procedures , 2002, BMJ : British Medical Journal.

[16]  Lauren E. Manning,et al.  The scent of Mycobacterium tuberculosis--part II breath. , 2009, Tuberculosis.

[17]  Q. Jöbsis,et al.  Exhaled volatile organic compounds predict exacerbations of childhood asthma in a 1-year prospective study , 2013, European Respiratory Journal.

[18]  J. Rathmell,et al.  Results of the two incidence screenings in the National Lung Screening Trial. , 2013, The New England journal of medicine.

[19]  Hossam Haick,et al.  Volatile organic compounds of lung cancer and possible biochemical pathways. , 2012, Chemical reviews.

[20]  J W Dallinga,et al.  Breath analysis as a potential diagnostic tool for tuberculosis. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[21]  S. Chambers,et al.  The scent of Mycobacterium tuberculosis. , 2008, Tuberculosis.

[22]  Jill P. Mesirov,et al.  Criteria for the use of omics-based predictors in clinical trials , 2013, Nature.

[23]  Charles Auffray,et al.  Application of ’omics technologies to biomarker discovery in inflammatory lung diseases , 2013, European Respiratory Journal.

[24]  B. Cooper,et al.  Using a Web-Based Application to Define the Accuracy of Diagnostic Tests When the Gold Standard Is Imperfect , 2013, PloS one.

[25]  Jiangjiang Zhu,et al.  Breathprints of model murine bacterial lung infections are linked with immune response , 2014, European Respiratory Journal.

[26]  Adam P. Arkin,et al.  Interactive XCMS Online: Simplifying Advanced Metabolomic Data Processing and Subsequent Statistical Analyses , 2014, Analytical chemistry.

[27]  R. Dweik,et al.  Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study , 2014, Alimentary pharmacology & therapeutics.

[28]  C Hoeschen,et al.  Effects of diet-matrix on volatile organic compounds in breath in diet-induced obese mice , 2014, Journal of breath research.

[29]  Trinad Chakraborty,et al.  Clinical Application of Volatile Organic Compound Analysis for Detecting Infectious Diseases , 2013, Clinical Microbiology Reviews.

[30]  B. de Lacy Costello,et al.  A review of the volatiles from the healthy human body , 2014, Journal of breath research.

[31]  Joshua T. Morgan,et al.  Characterization of Volatile Organic Compounds in Human Leukocyte Antigen Heterologous Expression Systems: a Cell's “Chemical Odor Fingerprint” , 2012, Chembiochem : a European journal of chemical biology.

[32]  J. Lindon,et al.  Scaling and normalization effects in NMR spectroscopic metabonomic data sets. , 2006, Analytical chemistry.

[33]  H. Haick,et al.  Unique volatolomic signatures of TP53 and KRAS in lung cells , 2014, British Journal of Cancer.

[34]  D. Blake,et al.  The clinical potential of exhaled breath analysis for diabetes mellitus. , 2012, Diabetes research and clinical practice.

[35]  Peter J. Sterk,et al.  Volatile Metabolites of Pathogens: A Systematic Review , 2013, PLoS pathogens.

[36]  A. Wilson.  Advances in Electronic-Nose Technologies for the Detection of Volatile Biomarker Metabolites in the Human Breath , 2015, Metabolites.

[37]  G. Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement , 2015, Annals of Internal Medicine.

[38]  H. Haick,et al.  Diagnosing lung cancer in exhaled breath using gold nanoparticles. , 2009, Nature nanotechnology.

[39]  C. Auffray,et al.  Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014. , 2015, American journal of respiratory and critical care medicine.

[40]  P. Sterk,et al.  Exhaled breath analysis by electronic nose in airways disease. Established issues and key questions , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[41]  A Abu-Hanna,et al.  Exhaled breath analysis with electronic nose technology for detection of acute liver failure in rats. , 2014, Biosensors & bioelectronics.

[42]  Bogusław Buszewski,et al.  Analysis of exhaled breath for disease detection. , 2014, Annual review of analytical chemistry.

[43]  David Smith,et al.  Breath analysis of ammonia, volatile organic compounds and deuterated water vapor in chronic kidney disease and during dialysis. , 2014, Bioanalysis.

[44]  Hossam Haick,et al.  Assessment, origin, and implementation of breath volatile cancer markers. , 2014, Chemical Society reviews.

[45]  J. Câmara,et al.  Breath Analysis as a Potential and Non-Invasive Frontier in Disease Diagnosis: An Overview , 2015, Metabolites.

[46]  Joachim D Pleil,et al.  Clinical breath analysis: discriminating between human endogenous compounds and exogenous (environmental) chemical confounders , 2013, Journal of breath research.

[47]  Douglas B. Kell,et al.  Statistical strategies for avoiding false discoveries in metabolomics and related experiments , 2007, Metabolomics.

[48]  Xiang Zhang,et al.  A method of aligning peak lists generated by gas chromatography high-resolution mass spectrometry. , 2013, The Analyst.

[49]  Bettina Zelger,et al.  Comparative analyses of volatile organic compounds (VOCs) from patients, tumors and transformed cell lines for the validation of lung cancer-derived breath markers , 2014, Journal of breath research.

[50]  Jeroen S. Dickschat,et al.  Bacterial volatiles: the smell of small organisms. , 2007, Natural product reports.

[51]  I. Horváth,et al.  Standardised exhaled breath collection for the measurement of exhaled volatile organic compounds by proton transfer reaction mass spectrometry , 2013, BMC Pulmonary Medicine.

[52]  P. Sterk,et al.  Breathomics in lung disease. , 2015, Chest.

[53]  Jens Herbig,et al.  Towards standardization in the analysis of breath gas volatiles , 2014, Journal of breath research.

[54]  Agnieszka Smolinska,et al.  Profiling of Volatile Organic Compounds in Exhaled Breath As a Strategy to Find Early Predictive Signatures of Asthma in Children , 2014, PloS one.

[55]  K. Darwiche,et al.  Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects , 2015, International journal of chronic obstructive pulmonary disease.

[56]  Paolo Montuschi,et al.  The Electronic Nose in Respiratory Medicine , 2012, Respiration.

[57]  J. Knottnerus,et al.  The standards for reporting of diagnostic accuracy. , 2003, Journal of clinical epidemiology.

[58]  P. Aloy,et al.  Unveiling the role of network and systems biology in drug discovery. , 2010, Trends in pharmacological sciences.

[59]  Raymond A Martino,et al.  Detecting cancer by breath volatile organic compound analysis: a review of array-based sensors , 2014, Journal of breath research.

[60]  Ralf Zimmermann,et al.  Automated needle trap heart-cut GC/MS and needle trap comprehensive two-dimensional GC/TOF-MS for breath gas analysis in the clinical environment. , 2010, Analytical chemistry.

[61]  Eduardo Gotuzzo,et al.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study , 2011, The Lancet.

[62]  David I. Ellis,et al.  A tutorial review: Metabolomics and partial least squares-discriminant analysis--a marriage of convenience or a shotgun wedding. , 2015, Analytica chimica acta.

[63]  Graham Bothamley,et al.  Point-of-care breath test for biomarkers of active pulmonary tuberculosis. , 2012, Tuberculosis.

[64]  B. Costello,et al.  The human volatilome: volatile organic compounds (VOCs) in exhaled breath, skin emanations, urine, feces and saliva , 2014, Journal of breath research.

[65]  Sonja Peters,et al.  Parameter selection for peak alignment in chromatographic sample profiling: objective quality indicators and use of control samples , 2009, Analytical and bioanalytical chemistry.

[66]  Ameen Abu-Hanna,et al.  Glucose prediction by analysis of exhaled metabolites – a systematic review , 2014, BMC Anesthesiology.

[67]  Claude Gravel,et al.  Adeno-associated Virus–mediated Delivery of a Recombinant Single-chain Antibody Against Misfolded Superoxide Dismutase for Treatment of Amyotrophic Lateral Sclerosis , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  J. Cowan,et al.  Predicting steroid responsiveness in patients with asthma using exhaled breath profiling , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[69]  Yvonne Vergouwe,et al.  External validity of risk models: Use of benchmark values to disentangle a case-mix effect from incorrect coefficients. , 2010, American journal of epidemiology.

[70]  Robert Schmieder,et al.  Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation , 2014, The ISME Journal.

[71]  Matej Oresic,et al.  MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data , 2010, BMC Bioinformatics.

[72]  Jaeyun Sung,et al.  Molecular signatures from omics data: From chaos to consensus , 2012, Biotechnology journal.

[73]  D. Blake,et al.  Ethane and n-pentane in exhaled breath are biomarkers of exposure not effect , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[74]  Adnan Custovic,et al.  Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. , 2011, The Journal of allergy and clinical immunology.

[75]  F. V. van Schooten,et al.  The versatile use of exhaled volatile organic compounds in human health and disease , 2012, Journal of breath research.

[76]  Martin Sklorz,et al.  Phase-resolved real-time breath analysis during exercise by means of smart processing of PTR-MS data , 2011, Analytical and bioanalytical chemistry.

[77]  Ngoc A. Dang,et al.  Rapid diagnosis of TB using GC-MS and chemometrics. , 2013, Bioanalysis.